Abstract
Pregnancy in women with systemic lupus erythematosus presents significant clinical challenges due to heightened risks of complications for both mother and fetus. Therapeutic management must be carefully tailored to safeguard maternal health while ensuring optimal fetal development. This review explores pharmacological treatments used during pregnancy in women with lupus, focusing on medication safety profiles, risk-benefit analyses of available therapeutic options, and specific challenges posed by comorbidities such as antiphospholipid syndrome and vaccination considerations. Although significant advances have been made in managing lupus during pregnancy, many treatments, particularly biologic therapies, still lack sufficient evidence for unrestricted use. This underscores the necessity for vigilant monitoring and individualized treatment protocols. Preconception consultation remains crucial for optimizing therapeutic strategies, ensuring appropriate medication adjustments prior to conception. A coordinated multidisciplinary approach is essential to navigate these complexities and achieve favorable outcomes for both mother and child.

This publication has 104 references indexed in Scilit: